+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
BIOGEN BIOGEN

Biogen Pharmachem Industries Share Price

 
66.67% Fall from 52W High

 

Biogen Pharmachem Industries live price: ₹0.31.

Biogen Pharmachem Industries Performance

  • Today's Low
  • ₹0
  • Today's High
  • ₹0
  • 52 Week Low
  • ₹0
  • 52 Week High
  • ₹1
  • Open Price₹0
  • Previous Close₹0
  • Volume2,866,483
  • 50 DMA₹0.30
  • 100 DMA₹0.40
  • 200 DMA₹0.50

Biogen Pharmachem Industries Chart

Investment Returns

  • Over 1 Month -6.06%
  • Over 3 Month -27.91%
  • Over 6 Month -39.22%
  • Over 1 Year -61.25%

Smart Investing Starts Here Start SIP with Biogen Pharmachem Industries for Steady Growth!

Invest Now

Biogen Pharmachem Industries Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 34.1
  • PEG Ratio
  • 0.1
  • Market Cap Cr
  • 33
  • P/B Ratio
  • 0.3
  • Average True Range
  • 0.02
  • EPS
  • 0
  • Dividend Yield
  • 0
  • MACD Signal
  • -
  • RSI
  • 45.64
  • MFI
  • 33.83

Latest Stock News Updates

Biogen Pharmachem Industries Ltd - 531752 - Board Meeting Intimation for Compliance Of Regulation 29 Of SEBI (LODR) Regulations, 2015 - Intimation Of Board Meeting.

Biogen Pharmachem Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/08/2026 ,inter alia, to consider and approve Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that a meeting of the Board of Directors of the Company will be held on Wednesday 5th August 2026 inter alia, to consider following businesses: - 1 To approve and take on record the Un-Audited Financial Results of the Company for the first quarter ended on 30th June 2026. 2.) Any other matter with the permission of the board which the Board may think fit. Please take the above intimation in your records. Thanking You.

Biogen Pharmachem Industries Ltd - 531752 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

PFA

Biogen Pharmachem Industries Ltd - 531752 - Closure of Trading Window

PFA

Biogen Pharmachem Industries Financials

Biogen Pharmachem Industries Technicals

EMA & SMA

Current Price
₹0.31
-0.01 (-3.12%)
pointer
  • Bearish Moving Average 5
  • Bullish Moving Average 11
  • 20 Day
  • ₹0.30
  • 50 Day
  • ₹0.30
  • 100 Day
  • ₹0.40
  • 200 Day
  • ₹0.50

Resistance and Support

0.3 Pivot Speed
  • R3 0.30
  • R2 0.30
  • R1 0.30
  • S1 0.30
  • S2 0.30
  • S3 0.30

Biogen Pharmachem Industries Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-08-05 Quarterly Results
2026-05-14 Audited Results
2026-03-23 Bonus issue
2026-02-11 Quarterly Results (Revised)
2025-11-07 Quarterly Results
Date Purpose Remarks
2003-07-21 Split Face value changed from Rs. 10/- to Rs. 1/-
Date Purpose Remarks
2026-05-15 Bonus Bonus issue of equity shares in the ratio of 1:6 of Re. 1/-..

Biogen Pharmachem Industries Shareholding Pattern

100%
0%
0%

About Biogen Pharmachem Industries

Biogen Pharmachem Industries is engaged in the financial services sector, including trading in shares, securities, and commodities. View More
  • NSE Symbol
  • BIOGEN
  • BSE Symbol
  • 531752
  • ISIN
  • INE703D01023

Similar Stocks to Biogen Pharmachem Industries

Biogen Pharmachem Industries FAQs

Biogen Pharmachem Industries share price is ₹0 As on 22 July, 2026 | 19:36

The Market Cap of Biogen Pharmachem Industries is ₹32.6 Cr As on 22 July, 2026 | 19:36

The P/E ratio of Biogen Pharmachem Industries is 34.1 As on 22 July, 2026 | 19:36

The PB ratio of Biogen Pharmachem Industries is 0.3 As on 22 July, 2026 | 19:36

The 52 week High & Low of Biogen Pharmachem Industries is ₹0.9/₹0.3 respectively As on 22 July, 2026 | 19:36

Open FREE Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23